<?xml version="1.0" encoding="UTF-8"?>
<?xml-model href="http://docbook.org/xml/5.1/rng/docbook.rng" schematypens="http://relaxng.org/ns/structure/1.0"?>
<?xml-model href="http://docbook.org/xml/5.1/rng/docbook.rng" type="application/xml" schematypens="http://purl.oclc.org/dsdl/schematron"?>
<book version="5.1" xmlns="http://docbook.org/ns/docbook" xmlns:xlink="http://www.w3.org/1999/xlink">
  <info>
        <title>Clinical Decision Support (CDS) Content and Health Level 7 (HL7)-Compliant Knowledge
            Artifacts (KNARTs)</title>
        <subtitle>Cardiology: Venous Thromboembolism (VTE) Prophylaxis Clinical Content White
            Paper</subtitle>
        <copyright>
            <year>March</year>
            <year>2018</year>
            <holder>B3 Group, Inc.</holder>
        </copyright>
        <legalnotice>
            <title>B3 Group, Inc.</title>
            <para>NOTICE OF GOVERNMENT COPYRIGHT LICENSE AND UNLIMITED RIGHTS LICENSE</para>
            <para>Licensed under the Apache License, Version 2.0 (the "License"); you may not use
                this file except in compliance with the License.</para>
            <para>You may obtain a copy of the License at <link
                    xlink:href="http://www.apache.org/licenses/LICENSE-2.0"
                    >http://www.apache.org/licenses/LICENSE-2.0</link>
            </para>
            <para>Unless required by applicable law or agreed to in writing, software distributed
                under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR
                CONDITIONS OF ANY KIND, either express or implied. See the License for the specific
                language governing permissions and limitations under the License.</para>
            <para>Portions of this content are derivative works from content produced by Cognitive
                Medical Systems, Inc. licensed under the Apache License, Version 2.0.</para>
            <para>Additional portions of this content are derivative works from content contributed
                by Motive Medical Intelligence Inc., under Creative Commons Attribution-ShareAlike
                4.0.</para>
            <para>Contributions from 2013-2018 were performed either by US Government employees, or
                under US Veterans Health Administration contracts.</para>
            <para>US Veterans Health Administration contributions by government employees are work
                of the U.S. Government and are not subject to copyright protection in the United
                States. Portions contributed by government employees are USGovWork (17USC §105). Not
                subject to copyright.</para>
            <para>See: <link xlink:href="https://www.usa.gov/government-works"
                    >https://www.usa.gov/government-works</link>
            </para>
            <para>Contribution by contractors to the US Veterans Health Administration during this
                period are contractually contributed under the Apache License, Version 2.0 and US
                Government sponsorship is acknowledged under Contract VA118-16-D-1008, Task Order
                VA11817F10080007.</para>
        </legalnotice>
        <copyright>
            <year>2018</year>
            <holder>Cognitive Medical Systems, Inc.</holder>
        </copyright>
        <legalnotice>
            <title>Cognitive Medical Systems, Inc.</title>
            <para>Licensed under the Apache License, Version 2.0 (the "License"); you may not use
                this file except in compliance with the License.</para>
            <para>You may obtain a copy of the License at <link
                    xlink:href="http://www.apache.org/licenses/LICENSE-2.0"
                    >http://www.apache.org/licenses/LICENSE-2.0</link>
            </para>
            <para>Unless required by applicable law or agreed to in writing, software distributed
                under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR
                CONDITIONS OF ANY KIND, either express or implied. See the License for the specific
                language governing permissions and limitations under the License.</para>
            <para>This and related content produced by Cognitive Medical Systems, Inc. licensed
                under the Apache License, Version 2.0 is available at: <link
                    xlink:href="https://bitbucket.org/cogmedsys/hl7-kas-examples"
                    >https://bitbucket.org/cogmedsys/hl7-kas-examples</link>
            </para>
            <para>Additional portions of this content are derivative works from content contributed
                by Motive Medical Intelligence Inc., under Creative Commons Attribution-ShareAlike
                4.0. <link xlink:href="https://bitbucket.org/cogmedsys/kas-source-material"
                    >https://bitbucket.org/cogmedsys/kas-source-material</link>
            </para>
            <para>Contributions from 2013-2018 were performed either by US Government employees, or
                under US Veterans Health Administration contracts.</para>
            <para>US Veterans Health Administration contributions by government employees are work
                of the U.S. Government and are not subject to copyright protection in the United
                States. Portions contributed by government employees are USGovWork (17USC §105). Not
                subject to copyright. See: <link xlink:href="https://www.usa.gov/government-works"
                    >https://www.usa.gov/government-works</link>
            </para>
            <para>Contribution by contractors to the US Veterans Health Administration during this
                period are contractually contributed under the Apache License, Version 2.0 and US
                Government sponsorship is acknowledged under Contract VA118-16-D-1008-0007.</para>
        </legalnotice>
        <authorgroup>
            <author>
                <personname>
                    <surname>Department of Veterans Affairs (VA)</surname>
                </personname>
            </author>
            <author>
                <orgname><inlinemediaobject>
                        <alt>Department of Veteran's Affairs Logo</alt>
                        <imageobject>
                            <imagedata align="center"
                                fileref="../../../../../Resources/VASealColor.jpg"
                                contentwidth="2in" contentdepth="2in" scalefit="0"/>
                        </imageobject>
                    </inlinemediaobject></orgname>
            </author>
            <author>
                <orgname>Knowledge Based Systems (KBS)</orgname>
            </author>
            <author>
                <orgname>Office of Informatics and Information Governance (OIIG)</orgname>
            </author>
            <author>
                <orgname>Clinical Decision Support (CDS)</orgname>
            </author>
        </authorgroup>
        <abstract>
            <info>
                <title>Contract: VA118-16-D-1008, Task Order (TO): VA-118-16-F-1008-0007</title>
            </info>
            <para>
                <table frame="all" rowsep="1" colsep="1">
                    <title>Relevant KNART Information: Cardiology: Venous Thromboembolism (VTE)
                        Prophylaxis</title>
                    <tgroup cols="2" align="left">
                        <thead>
                            <row valign="bottom">
                                <entry valign="middle" align="left"> KNART Name</entry>
                                <entry valign="middle" align="left">Associated CLIN</entry>
                            </row>
                        </thead>
                        <tbody>
                            <row>
                                <entry>VTE Prophylaxis - Order Set</entry>
                                <entry>CLIN0008CA</entry>
                            </row>
                        </tbody>
                    </tgroup>
                </table>
            </para>
        </abstract>
        <pubdate>April 2018</pubdate>
        <edition>Version 1.1</edition>
        <revhistory>
            <revision>
                <revnumber>1.1</revnumber>
                <date>4/30/2018</date>
                <authorinitials>Kathleen Keating</authorinitials>
                <revremark>Revised Final per PO comments</revremark>
            </revision>
            <revision>
                <revnumber>1.0</revnumber>
                <date>12/21/2017</date>
                <authorinitials>Jennifer Reed and Steve Mahalec</authorinitials>
                <revremark>Final DocBook transformation</revremark>
            </revision>
            <revision>
                <revnumber>0.15</revnumber>
                <date>12/15/2017</date>
                <authorinitials>Steve Mahalec</authorinitials>
                <revremark>DocBook QA</revremark>
            </revision>
            <revision>
                <revnumber>0.14</revnumber>
                <date>10/16/2017</date>
                <authorinitials>Steve Mahalec</authorinitials>
                <revremark>Technical QA review; prep for formal review submission</revremark>
            </revision>
            <revision>
                <revnumber>0.13</revnumber>
                <date>10/16/2017</date>
                <authorinitials>Kathleen Keating</authorinitials>
                <revremark>QA review</revremark>
            </revision>
            <revision>
                <revnumber>0.12</revnumber>
                <date>10/13/2017</date>
                <authorinitials>Ralph Ruocco</authorinitials>
                <revremark>Incorporated edits per clinical review</revremark>
            </revision>
            <revision>
                <revnumber>0.11</revnumber>
                <date>10/13/2017</date>
                <authorinitials>Rocky Reston</authorinitials>
                <revremark>Clinical review</revremark>
            </revision>
            <revision>
                <revnumber>0.10</revnumber>
                <date>10/06/2017</date>
                <authorinitials>Nicholas Rains</authorinitials>
                <revremark>Clinical review</revremark>
            </revision>
            <revision>
                <revnumber>0.9</revnumber>
                <date>09/24/2017</date>
                <authorinitials>Ralph Ruocco</authorinitials>
                <revremark>Template revision per PO recommendations</revremark>
            </revision>
            <revision>
                <revnumber>0.8</revnumber>
                <date>09/05/2017</date>
                <authorinitials>Vida Dunie</authorinitials>
                <revremark>QA/Tech Writer review</revremark>
            </revision>
            <revision>
                <revnumber>0.7</revnumber>
                <date>09/05/2017</date>
                <authorinitials>Rocky Reston</authorinitials>
                <revremark>Clinical review</revremark>
            </revision>
            <revision>
                <revnumber>0.6</revnumber>
                <date>08/18/2017</date>
                <authorinitials>Wendelyn Bradley</authorinitials>
                <revremark>Incorporation of SME input</revremark>
            </revision>
            <revision>
                <revnumber>0.5</revnumber>
                <date>08/17/2017</date>
                <authorinitials>Rocky Reston</authorinitials>
                <revremark>SME Review/Approval of CCWP Draft</revremark>
            </revision>
            <revision>
                <revnumber>0.4</revnumber>
                <date>08/11/2017</date>
                <authorinitials>Ralph Ruocco</authorinitials>
                <revremark>Technical Edit</revremark>
            </revision>
            <revision>
                <revnumber>0.3</revnumber>
                <date>08/09/2017</date>
                <authorinitials>Ralph Ruocco</authorinitials>
                <revremark>Motive Data added</revremark>
            </revision>
            <revision>
                <revnumber>0.2</revnumber>
                <date>08/01/2017</date>
                <authorinitials>Ralph Ruocco</authorinitials>
                <revremark>Template update</revremark>
            </revision>
            <revision>
                <revnumber>0.1</revnumber>
                <date>07/24/2017</date>
                <authorinitials>Ralph Ruocco</authorinitials>
                <revremark>Initial draft</revremark>
            </revision>
        </revhistory>
    </info>

  <preface>
    <title>VA Subject Matter Expert (SME) Panel</title>

    <informaltable frame="all" xml:id="va.SME.List">
      <tgroup cols="3">
        <thead>
          <row>
            <entry>Name</entry>

            <entry>Title</entry>

            <entry>Project Role</entry>
          </row>
        </thead>

        <tbody>
          <row>
            <entry>Bruce Bray, MD</entry>

            <entry>Professor, Cardiovascular Medicine, University of Utah
            School of Medicine; Staff Cardiologist, Salt Lake City VA Medical
            Center (<glossterm>VAMC</glossterm>)</entry>

            <entry>SME, Primary</entry>
          </row>

          <row>
            <entry>Scott Wall, MD</entry>

            <entry>Assistant Professor, Cardiovascular Medicine, University of Utah; School of
                            Medicine Staff Cardiologist, Electrophysiology, Salt Lake City VAMC,
                            Salt Lake City, UT 84148</entry>

            <entry>SME, Secondary</entry>
          </row>

          <row>
            <entry>Aiden Abidov, MD, PhD</entry>

            <entry>Professor of Medicine, Wayne State University; Section Chief, Cardiology, John
                            Dingell VAMC, 4646 John R St, Detroit, MI 48201</entry>

            <entry>SME</entry>
          </row>

          <row>
            <entry>Claibe Yarbrough, MD</entry>

            <entry>National Program Director, North Texas VHCS, Pulmonary/Critical Care/Sleep
                            Medicine, Dallas, TX, 4500 S Lancaster, Dallas, TX 75216</entry>

            <entry>SME</entry>
          </row>

          <row>
            <entry>Benjamin Brooke,MD</entry>

            <entry>Attending SLC VAMC, Surgery Services, Salt Lake City, UT, 508 Fulton St, Durham,
                            NC 27705</entry>

            <entry>SME</entry>
          </row>
        </tbody>
      </tgroup>
    </informaltable>
  </preface>

  <preface>
    <title>Introduction</title>

      <para>The VA is committed to improving the ability of clinicians to provide
          care for patients while increasing quality, safety, and efficiency.
          Recognizing the importance of standardizing clinical knowledge in support of
          this goal, VA is implementing the Health Level 7
          (<acronym><glossterm>HL7</glossterm></acronym>) Knowledge Artifact
          Specification for a wide range of VA clinical use cases. Knowledge
          Artifacts, referred to as (<acronym>
              <glossterm>KNARTs</glossterm></acronym>), enable the structuring and
          encoding of clinical knowledge so the knowledge can be integrated with
          electronic health records to enable clinical decision support.</para>
      
      <para>The purpose of this Clinical Content White Paper
          (<acronym><glossterm>CCWP</glossterm></acronym>) is to capture the clinical
          context and intent of <acronym><glossterm>KNART</glossterm></acronym> use
          cases in sufficient detail to provide the
          <acronym><glossterm>KNART</glossterm></acronym> authoring team with the
          clinical source material to construct the corresponding knowledge artifacts
          using the HL7 Knowledge Artifact Specification. This paper has been
          developed using material from a variety of sources: VA artifacts, clinical
          practice guidelines, evidence in the body of medical literature, and
          clinical expertise. After reviewing these sources, the material has been
          synthesized and harmonized under the guidance of VA subject matter experts
          to reflect clinical intent for this use case.</para>
      
      <para>Unless otherwise noted, items within this white paper (e.g.,
          documentation template fields, orderable items, etc.) are chosen to reflect
          the clinical intent at the time of creation. To provide an exhaustive list
          of all possible items and their variations is beyond the scope of this
          work.</para>
  </preface>

  <preface>
    <title>Conventions Used</title>
      <para>Conventions used within the knowledge artifact descriptions
          include:</para>
      
      <itemizedlist mark="none">
          <listitem>
              <para><emphasis>&lt;obtain&gt;</emphasis>: Indicates a prompt to obtain
                  the information listed <itemizedlist mark="bullet">
                      <listitem>
                          <para>If possible, the requested information should be obtained
                              from the underlying system(s). Otherwise, prompting the user for
                              information may be required</para>
                      </listitem>
                      
                      <listitem>
                          <para>The technical and clinical notes associated with a section
                              should be consulted for specific constraints on the information
                              (e.g., time-frame, patient interview, etc.)</para>
                      </listitem>
                      
                      <listitem>
                          <para>Default Values: Unless otherwise noted, &lt;obtain&gt;
                              indicates to obtain the most recent observation. It is recognized
                              that this default time-frame value may be altered by future
                              implementations</para>
                      </listitem>
                  </itemizedlist></para>
          </listitem>
          
          <listitem>
              <para><emphasis>[...]</emphasis>: Square brackets enclose explanatory text that indicates some
                  action on the part of the clinical user, or general guidance to the clinical or technical
                  teams. Examples include, but are not limited to:</para>
              
              <itemizedlist mark="none">
                  <listitem>
                      <para><emphasis>[Begin ...]</emphasis>, <emphasis>[End
                          ...]</emphasis>: Indicates the start and end of specific areas to
                          clearly delineate them for technical purposes.</para>
                      
                      <para><emphasis>[Activate ...]</emphasis>: Initiates another
                          knowledge artifact or knowledge artifact section.</para>
                      
                      <para><emphasis>[Section Prompt: ...]</emphasis>: If this section is
                          applicable, then the following prompt should be displayed to the
                          user.</para>
                      
                      <para><emphasis>[Section Selection Behavior: ...]</emphasis>:
                          Indicates technical constraints or considerations for the selection
                          of items within the section.</para>
                      
                      <para><emphasis>[Attach: ...]</emphasis>: Indicates that the
                          specified item should be attached to the documentation template if
                          available.</para>
                      
                      <para><emphasis>[Link: ...]</emphasis>: Indicates that rather than
                          attaching an item, a link should be included in the documentation
                          template.</para>
                      
                      <para><emphasis>[Clinical Comment: ...]</emphasis>: Indicates
                          clinical rationale or guidance.</para>
                      
                      <para><emphasis>[Technical Note: ...]</emphasis>: Indicates
                          technical considerations or notes.</para>
                      
                      <para><emphasis>[If ...]</emphasis>: Indicates the beginning of a
                          conditional section.</para>
                      
                      <para><emphasis>[Else, ...]</emphasis>: Indicates the beginning of
                          the alternative branch of a conditional section.</para>
                      
                      <para><emphasis>[End if ...]</emphasis>: Indicates the end of a
                          conditional section.</para>
                  </listitem>
              </itemizedlist>
          </listitem>
          
          <listitem>
              <para>☐ <emphasis>[Check box]</emphasis>: Indicates items that should be
                  selected based upon the section selection behavior.</para>
          </listitem>
      </itemizedlist>
  </preface>

  <chapter>
    <title>Cardiology: Venous Thromboembolism Prophylaxis</title>

    <section>
      <title>Clinical Context</title>
            <para>[Begin Clinical Context.]</para>

      <para>The Venous Thromboembolism (<acronym><glossterm>VTE</glossterm></acronym>) Prophylaxis KNART is intended
                for users caring for hospitalized adult patients. This KNART is designed to
                facilitate ordering for mechanical and/or pharmacological VTE prophylaxis in medical
                and surgical inpatients without known VTE.</para>

        <para>The American Academy of Orthopedic Surgeons
                    (<acronym><glossterm>AAOS</glossterm></acronym>) and the American College of
                Chest Physicians (<acronym><glossterm>ACCP</glossterm></acronym>) are the primary
                sources for this KNART:<itemizedlist>
                    <listitem>
                        <para>American Academy of Orthopaedic Surgeons. Preventing venous
                            thromboembolic disease in patients undergoing elective hip and knee
                            arthroplasty: evidence-based guideline and evidence report, second
                            edition. American Academy of Orthopaedic Surgeons website.
                            https://www.aaos.org/research/guidelines/VTE/VTE_full_guideline.pdf.
                            Published 2011.</para>
                    </listitem>
                </itemizedlist></para>

       <itemizedlist>

        <listitem>
          <para>Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in
          nonorthopedic surgical patients: Antithrombotic Therapy and
          Prevention of Thrombosis, 9th ed: American College of Chest
          Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012
          Feb;141(2 Suppl):e227S-e277S.</para>
        </listitem>

        <listitem>
          <para>Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in
          nonsurgical patients: Antithrombotic Therapy and Prevention of
          Thrombosis, 9th ed: American College of Chest Physicians
          Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2
          Suppl):e195S-e226S.</para>
        </listitem>
                <listitem>
                    <para>VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN
                        Pharmacist Executives, Direct Oral Anticoagulants (DOACs) (formerly called
                        TSOACs), Rivaroxaban (Xarelto), Apixaban (Eliquis), and Dabigatran
                        (Pradaxa), Criteria for Use for VTE Prophylaxis for Total Hip or Total Knee
                        Replacement Surgery. February 2015</para>
                </listitem>
      </itemizedlist>

      <para>This KNART also includes a link to the American College of Chest Physicians Pregnancy
                Anticoagulation Guidelines in Appendix C (<link
                    xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/"/>), although
                pregnancy shall not be a primary focus of the KNART. The clinical context domains
                are summarized in Table 1, below.</para>

      <para>
        <table>
          <title>Clinical Context Domains</title>

          <tgroup cols="2">
            <tbody>
              <row>
                <entry>Target User</entry>

                <entry>Hospitalist, residents, and other ordering providers
                involved in managing the patient cohort, and nurses</entry>
              </row>

              <row>
                <entry>Patient</entry>

                <entry>Adult inpatients without known VTE and not pregnant</entry>
              </row>

              <row>
                <entry>Priority</entry>

                <entry>Routine</entry>
              </row>

              <row>
                <entry>Specialty</entry>

                <entry>Medical and/or Surgical Service</entry>
              </row>

              <row>
                <entry>Location</entry>

                <entry>Inpatient</entry>
              </row>
            </tbody>
          </tgroup>
        </table>
      </para>
            <para>[End Clinical Context.]</para>
    </section>

    <section>
      <title>Knowledge Artifacts</title>
            <para>[Begin Knowledge Artifacts.]</para>

      <para>The CDS knowledge artifact that defines the clinical use case is described in detail in
                the following sections:</para>

       <itemizedlist>
        <listitem>
          <para>Order Set: VTE KNART</para>

           <itemizedlist>
            <listitem>
              <para>Orderable items</para>
            </listitem>

            <listitem>
              <para>Logic for appropriate display of the order set</para>
            </listitem>
          </itemizedlist>
        </listitem>
      </itemizedlist>
            <para>[End Knowledge Artifacts.]</para>
    </section>
  </chapter>

  <chapter>
    <title>VTE Prophylaxis - Order Set</title>
        <para>[Begin VTE Prophylaxis - Order Set.]</para>

    <section>
      <title>Knowledge Narrative</title>
            <para>[Begin Knowledge Narrative.]</para>

      <para>[See Clinical Context in Chapter 1, Section 1.1.]</para>

      <para>Venous thromboembolism (VTE) is a common medical problem that results in substantial
                morbidity and mortality. Despite its prevalence, physicians often fail to appreciate
                the risks for VTE and often fail to recognize its signs and symptoms; this has led
                the National Academy of Sciences to cite it as a frequent cause of diagnostic error
                (National Academies of Sciences 2015). The problem of diagnostic error in VTE is
                compounded by therapeutic error—largely involving anticoagulants, which are
                perennially among the medications most often associated with adverse drug events
                (Shehab 2016). Remediating the problem requires the adoption of evidence-based
                guidelines, notably those of the American College of Chest Physicians for medical
                patients and nonorthopedic surgery patients and those of the American College of
                Orthopedic Surgeons for orthopedic surgery patients, across an entire health system.
                Rendering such guidelines operational requires meticulous curation of an array of
                granular elements across the full spectrum of clinical conditions (e.g., medical
                versus surgical patients, orthopedic versus nonorthopedic surgical patients,
                intracranial/spinal surgery, etc.) and the management of numerous comorbidities and
                factors that have potential to complicate care and predispose patients to iatrogenic
                bleeding (hemorrhagic diathesis, renal failure, etc.). Deploying such decision
                support within the VA system offers the potential for significant cost savings,
                improvement in patient care, and avoidance of preventable morbidity and
                mortality.</para>
            <para>[End Knowledge Narrative.]</para>
    </section>
        <section>
            <title>Resources and Risk Stratification: Medical Patients</title>
            <para>[Begin Resources and Risk Stratification: Medical Patients.]</para>
            <para>[Section Prompt: This section should be available for all medical
                patients.]</para>
            <para>[Technical Note: A link to the Padua prediction scoring algorithm
                (https://www.mdcalc.com/padua-prediction-score-risk-vte) should be provided.]</para>
            <para>[End Resources and Risk Stratification: Medical Patients.]</para>
        </section>

    <section>
            <title>Medications: Medical Patients</title>
            <para>[Begin Medications: Medical Patients.]</para>
            <para>[Section Prompt: Medications: Medical Patients.]</para>
            <para>[Technical Note: This section should be available for all medical patients
                requiring pharmacological VTE prophylaxis.]</para>
            <para>[Section Prompt: Acutely Ill Patients - This subsection applies to all acutely ill
                medical patients at increased risk of thrombosis who are not bleeding or at high
                risk for bleeding.]</para>
             <itemizedlist mark="none">
                <listitem>
                    <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Heparin 5000 Units solution subcutaneous three times daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Fondaparinux 2.5 mg solution subcutaneous once daily
                        (routine)</para>
                </listitem>
            </itemizedlist>
            <para>[Section Prompt: Critically Ill Patients - This subsection applies to all
                critically ill medical patients at increased risk of thrombosis who are not bleeding
                or at high risk for bleeding.]</para>
             <itemizedlist mark="none">
                <listitem>
                    <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                        (routine)</para>
                </listitem>
            </itemizedlist>
            <para>[End Medications: Medical Patients.]</para>
        </section>
        <section>
            <title>Procedures: Medical Patients</title>
            <para>[Begin Procedures: Medical Patients.]</para>
            <para>[Section Prompt: Mechanical VTE Prophylaxis, Medical Patients]</para>
            <para>[Technical Note: This section should be available for all medical patients
                requiring mechanical VTE prophylaxis, particularly those who are at increased risk
                of bleeding events.]</para>
            <para>[Section Prompt: Acutely Ill Patients - This subsection applies to all acutely ill
                medical patients at increased risk of thrombosis who are bleeding or at high risk
                for major bleeding.] <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Graduated compression stockings (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Critically Ill Patients - This subsection applies to all
                critically ill medical patients at increased risk of thrombosis who are bleeding or
                at high risk for major bleeding.]</para>
            <para>
                 <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Graduated compression stockings (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[End Procedures: Medical Patients.]</para>
        </section>

    <section>
      <title>Resources and Risk Stratification: Nonorthopedic Surgical Patients</title>

      <para>[Begin Resources and Risk Stratification: Nonorthopedic Surgical Patients.]</para>
            <para>[Section Prompt: VTE Risk Stratification for surgical patients]</para>
            <para>[Technical Note: This section should be available for all nonorthopedic surgical
                patients.]</para>

      <para>[Technical Note: A link to the Rogers scoring algorithm (<link
                    xlink:href="http://www.journalacs.org/article/S1072-7515(07)00327-4/fulltext"
                    >http://www.journalacs.org/article/S1072-7515(07)00327-4/fulltext</link>) should
                be provided.]</para>
            <para>[Technical Note: A link to the Caprini scoring algorithm (<link
                    xlink:href="http://venousdisease.com/caprini-dvt-risk-assessment/"
                    >http://venousdisease.com/caprini-dvt-risk-assessment/</link>) should be
                provided.]</para>
            <para>[Technical Note: A link to the American College of Chest Physicians pregnancy
                anticoagulation guidelines (<link
                    xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/"
                    >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/</link>) should be
                provided.] </para>
            <para>[End Resources and Risk Stratification: Nonorthopedic Surgical Patients.]</para>
    </section>
        <section>
            <title>Activity: Nonorthopedic Surgical Patients</title>
            <para>[Begin Activity: Nonorthopedic Surgical Patients.]</para>
            <para/>
            <para>[Section Prompt: Activity Order for nonorthopedic surgical patients]</para>
            <para>[Technical Note: This section should be available for all nonorthopedic surgery
                patients requiring VTE prophylaxis.]</para>
            <para>[Section Prompt: General and Abdominal-Pelvic Surgery Patients at Very Low Risk
                for VTE]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ambulate with assistance 1 time per shift (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Bed to chair 1 time per shift (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Up ad lib now</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[End Activity: Nonorthopedic Surgical Patients.]</para>
        </section>
        <section>
            <title>Medications: Nonorthopedic Surgical Patients</title>
            <para>[Begin Medication: Nonorthopedic Surgical Patients.]</para>
            <para>[Section Prompt: Medications – Nonorthopedic Surgical Patients]</para>
            <para>[Technical Note: This section should be available for all nonorthopedic surgery
                patients requiring pharmacological VTE prophylaxis.]</para>
            <para>[Section Prompt: General and Abdominal-Pelvic Surgery Patients at Moderate Risk
                for VTE - This subsection applies to all general and abdominal-pelvic surgery
                patients at moderate risk for VTE who are not at high risk for major bleeding
                complications.]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Dalteparin 2500 Units solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                            (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: General and Abdominal-Pelvic Surgery Patients at High Risk for
                VTE - This subsection applies toall general and abdominal-pelvic surgery patients at
                high risk for VTE who are not at high risk for major bleeding complications.]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                            (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: General and Abdominal-Pelvic Surgery Patients at High Risk for
                VTE with Inability to Use Either LMWH or UFH - This subsection applies to all
                general and abdominal-pelvic surgery patients at high risk for VTE for whom both
                LMWH and UFH are contraindicated or unavailable and who are not at high risk for
                major bleeding complications.]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Fondaparinux 2.5 mg solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Aspirin 160 mg tablet oral once daily (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Cardiac Surgery Patients with Nonhemorrhagic Surgical
                Complications - This subsection applies to all cardiac surgery patients whose
                inpatient stay is prolonged by nonhemorrhagic surgical complications.] </para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Thoracic Surgery Patients at Moderate Risk for VTE - This
                subsection applies to all thoracic surgery patients at moderate risk for VTE who are
                not at high risk for perioperative bleeding.</para>
             <itemizedlist mark="none">
                <listitem>
                    <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                        (routine)</para>
                </listitem>
            </itemizedlist>
            <para>[Section Prompt: Thoracic Surgery Patients at High Risk for VTE - This subsection
                applies to all thoracic surgery patients at high risk for VTE who are not at high
                risk for perioperative bleeding.]</para>
             <itemizedlist mark="none">
                <listitem>
                    <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                        (routine)</para>
                </listitem>
            </itemizedlist>
            <para>[Section Prompt: Craniotomy Patients at Very High Risk for VTE - This subsection
                applies to all craniotomy patients at very high risk for VTE once adequate
                hemostasis is established and the risk of bleeding decreases.]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Fondaparinux 2.5 mg solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Spinal Surgery Patients at High Risk for VTE - This subsection
                applies to all spinal surgery patients at high risk for VTE once adequate hemostasis
                is established and the risk of bleeding decreases.]</para>
             <itemizedlist mark="none">
                <listitem>
                    <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                        (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Fondaparinux 2.5 mg solution subcutaneous once daily
                        (routine)</para>
                </listitem>
            </itemizedlist>
            <para>[Section Prompt: Major Trauma Patients - This subsection applies to all major
                trauma patients without contraindication.]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Heparin 5000 Units solution subcutaneous two times daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Enoxaparin 40 mg solution subcutaneous daily once 1 time
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[End Medications: Nonorthopedic Surgical Patients.]</para>
        </section>
        <section>
            <title>Procedures: Nonorthopedic Surgical Patients</title>
            <para>[Begin Procedures: Nonorthopedic Surgical Patients.]</para>
            <para>[Section Prompt: This section applies to all nonorthopedic surgical patients
                requiring mechanical VTE prophylaxis, particularly those who are at increased risk
                of bleeding events.]</para>
            <para>[Technical Note: This section should be available for all nonorthopedic surgical
                patients requiring mechanical VTE prophylaxis, particularly those who are at
                increased risk of bleeding events.]</para>
            <para>[Section Prompt: General and Abdominal-Pelvic Surgery Patients at Low Risk for
                VTE]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: General and Abdominal-Pelvic Surgery Patients at Moderate Risk
                for VTE]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: General and Abdominal-Pelvic Surgery Patients at High Risk for
                VTE]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Graduated compression stockings (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Cardiac Surgery Patients]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Thoracic Surgery Patients at Moderate Risk for VTE - This
                subsection applies to all thoracic surgery patients at moderate risk for VTE who are
                not at high risk for perioperative bleeding.] </para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Thoracic Surgery Patients at High Risk for VTE]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Graduated compression stockings (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Craniotomy Patients]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Spinal Surgery Patients]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Major Trauma Patients - This subsection applies to all major
                trauma patients without contraindication due to lower-extremity injury.]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[End Procedures: Nonorthopedic Surgical Patients.]</para>
        </section>

    <section>
      <title>Activity: Orthopedic Surgical Patients</title>

      <para>[Begin Activity: Orthopedic Surgical Patients.]</para>
            <para>[Section Prompt: Activity Orders for Orthopedic Surgical Patients]</para>
            <para>[Technical Note: This section should be available for all orthopedic surgical
                patients requiring VTE prophylaxis.]</para>
            <para>[Section Prompt: Consider early postoperative mobilization as indicated for the
                given surgery, context, and objectives related to weightbearing status.]</para>
            <para>[End Activity: Orthopedic Surgical Patients.]</para>
      
    </section>
        <section>
            <title>Medications: Orthopedic Surgical Patients</title>
            <para>[Begin Medications: Orthopedic Surgical Patients.]</para>
            <para>[Section Prompt: VTE Prophylaxis Medication Orders for Orthopedic Surgical
                Patients]</para>
            <para>[Technical Note: This section should be available for all orthopedic surgery
                patients requiring pharmacological VTE prophylaxis.]</para>
            <para>[Section Prompt: Total Hip Arthroplasty, Total Knee Arthroplasty, and Hip Fracture
                Surgery Patients]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Enoxaparin 30 mg solution subcutaneous every 12 hours
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Enoxaparin 40 mg solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Dalteparin 5000 Units solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Fondaparinux 2.5 mg solution subcutaneous once daily
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Warfarin tablet oral per protocol (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Apixaban 2.5 mg tablet oral two times daily (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Rivaroxaban 10 mg tablet oral once daily (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Aspirin 81 mg tablet oral once daily time with intermittent
                            pneumatic compression device begun intraoperatively and continued
                            postoperatively through duration of hospital stay (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[End Medications: Orthopedic Surgical Patients.]</para>
        </section>
        <section>
            <title>Procedures: Orthopedic Surgical Patients</title>
            <para>[Begin Procedures: Orthopedic Surgical Patients.]</para>
            <para>[Technical Note: This section should be available for all orthopedic surgical
                patients requiring mechanical VTE prophylaxis, particularly those who are at
                increased risk of bleeding events.]</para>
            <para>[Section Prompt: Total Hip Arthroplasty, Total Knee Arthroplasty, and Hip Fracture
                Surgery Patients]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Intermittent pneumatic compression (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[End Procedures: Orthopedic Surgical Patients.]</para>
        </section>

    <section>
            <title>Laboratory Tests</title>
            <para>[Begin Laboratory Tests.]</para>
            <para>[Technical Note: This section should be available for all patients requiring VTE
                prophylaxis.]</para>
            <para>[Section Prompt: The following laboratory studies should be considered for
                patients who will receive warfarin. These laboratory studies may also be indicated
                for patients on other medications for VTE prophylaxis if clinically indicated per
                clinician judgment.]</para>
             <itemizedlist mark="none">
                <listitem>
                    <para>&#x2610; Complete blood count once daily (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Basic metabolic panel once daily (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; Activated partial thromboplastin time once daily (routine)</para>
                </listitem>
                <listitem>
                    <para>&#x2610; International normalized ratio once daily (routine)</para>
                </listitem>
            </itemizedlist>
            <para>[End Laboratory Tests.]</para>
            <para>[End VTE Prophylaxis - Order Set.]</para>
        </section>
  </chapter>

  <bibliography>
    <title>Bibliography/Evidence</title>
        <biblioentry>
            <author>
                <orgname>American Academy of Orthopedic Surgeons</orgname>
            </author>
            <citetitle pubwork="webpage">Preventing venous thromboembolic disease in patients
                undergoing elective hip and knee arthroplasty: evidence-based guideline and evidence
                report, second edition</citetitle>
            <pubdate>Published 2011</pubdate>
            <bibliomisc>
                <link xlink:href="https://www.aaos.org/research/guidelines/VTE/VTE_full_guideline.pdf"/>
            </bibliomisc>
        </biblioentry>
        <biblioentry>
            <abbrev>Bates, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname>
                        <surname>Bates</surname>
                        <firstname>SM</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Greer</surname>
                        <firstname>IA</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Middledrop</surname>
                        <firstname>S</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Veenstra</surname>
                        <firstname>DL</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Prabulos</surname>
                        <firstname>AM</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Vandrik</surname>
                        <firstname>PO</firstname>
                    </personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy:
                Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of
                Chest Physicians Evidence-Based Clinical Practice Guidelines</citetitle>
            <citetitle pubwork="journal">Chest</citetitle>
            <pubdate>2012</pubdate>
            <volumenum>141</volumenum>
            <issuenum>2 Suppl</issuenum>
            <pagenums>e691S-e736S</pagenums>
        </biblioentry>

    <biblioentry>
      <author>
        <orgname>Caprini score: DVT risk assessment</orgname>
      </author>

      <citetitle pubwork="webpage">Venous Resource Center website</citetitle>

      <pubdate>August 8, 2017.</pubdate>

      <bibliomisc>
        <link xlink:href="http://venousdisease.com/caprini-dvt-risk-assessment/"/>
      </bibliomisc>
    </biblioentry>
        <biblioentry>
            <abbrev>Douketis, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname>
                        <surname>Douketis</surname>
                        <firstname>JD</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Spyropoulos</surname>
                        <firstname>AC</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Spencer</surname>
                        <firstname>FA</firstname>
                    </personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">Perioperative Management of Antithrombotic Therapy:
                Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of
                Chest Physicians Evidence-Based Clinical Practice Guidelines</citetitle>
            <citetitle pubwork="journal"> Chest</citetitle>
            <pubdate>2012</pubdate>
            <volumenum>141</volumenum>
            <issuenum>(2 Suppl)</issuenum>
            <pagenums>e326S-e350S</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Gould, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname>
                        <surname>Gould</surname>
                        <firstname>MK</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Garcia</surname>
                        <firstname>DA</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Wren</surname>
                        <firstname>SM</firstname>
                    </personname>
                </author>
            </authorgroup>
            <citetitle pubwork="article">Prevention of VTE in nonorthopedic surgical patients:
                Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of
                Chest Physicians Evidence-Based Clinical Practice Guidelines</citetitle>
            <bibliomisc>Chest</bibliomisc>
            <pubdate>February, 2012</pubdate>
            <volumenum>141</volumenum>
            <issuenum>(2 Suppl)</issuenum>
            <pagenums>e227S-e277S</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Kahn, 2012</abbrev>
            <authorgroup>
                <author>
                    <personname>
                        <surname>Kahn</surname>
                        <firstname>SR</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Lim</surname>
                        <firstname>W</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Dunn</surname>
                        <firstname>AS</firstname>
                    </personname>
                </author>
            </authorgroup>
            <citetitle pubwork="webpage">Prevention of VTE in nonsurgical patients: Antithrombotic
                Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians
                Evidence-Based Clinical Practice Guidelines</citetitle>
            <bibliomisc>Chest</bibliomisc>
            <pubdate>February 2012</pubdate>
            <volumenum>141</volumenum>
            <issuenum>(2 Suppl)</issuenum>
            <pagenums>e195S-e226S</pagenums>
        </biblioentry>

    <biblioentry>
      <author>
        <orgname>National Academies of Sciences, Engineering, and
        Medicine</orgname>
      </author>

      <citetitle pubwork="webpage">Improving Diagnosis in Health Care.
      Washington, DC: The National Academies Press</citetitle>

      <pubdate>2015</pubdate>

      <bibliomisc>
        <link xlink:href="https://doi.org/10.17226/21794"/>
      </bibliomisc>
    </biblioentry>

    <biblioentry>
      <author>
        <orgname>Padua Prediction Score for Risk of VTE</orgname>
      </author>

      <citetitle pubwork="webpage">MDCalc website</citetitle>

      <pubdate>August 8, 2017</pubdate>

      <bibliomisc>
        <link xlink:href="https://www.mdcalc.com/padua-prediction-score-risk-vte"/>
      </bibliomisc>
    </biblioentry>
        <biblioentry>
            <abbrev>Rogers, 2007</abbrev>
            <authorgroup>
                <author>
                    <personname>
                        <surname>Rogers</surname>
                        <firstname>SO,Jr</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Kilaru</surname>
                        <firstname>RK</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Hosokawa</surname>
                        <firstname>P</firstname>
                    </personname>
                </author>
            </authorgroup>
            <author>
                <personname>
                    <surname>Henderson</surname>
                    <firstname>WG</firstname>
                </personname>
            </author>
            <author>
                <personname>
                    <surname>Zinner</surname>
                    <firstname>MJ</firstname>
                </personname>
            </author>
            <author>
                <personname>
                    <surname>Khuri</surname>
                    <firstname>SF</firstname>
                </personname>
            </author>
            <citetitle pubwork="webpage">Multivariable predictors of postoperative venous
                thromboembolic events after general and vascular surgery: results from the patient
                safety in surgery study</citetitle>
            <bibliomisc> J Am Coll Surg.</bibliomisc>
            <pubdate>2007</pubdate>
            <volumenum>204</volumenum>
            <issuenum>(6)</issuenum>
            <pagenums>1211-1221</pagenums>
        </biblioentry>
        <biblioentry>
            <abbrev>Shehab, 2016</abbrev>
            <authorgroup>
                <author>
                    <personname>
                        <surname>Shehab</surname>
                        <firstname>N</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Lovegrove</surname>
                        <firstname>MC</firstname>
                    </personname>
                </author>
                <author>
                    <personname>
                        <surname>Geller</surname>
                        <firstname>AI</firstname>
                    </personname>
                </author>
            </authorgroup>
            <author>
                <personname>
                    <surname>Rose</surname>
                    <firstname>KO</firstname>
                </personname>
            </author>
            <author>
                <personname>
                    <surname>Weidle</surname>
                    <firstname>NJ</firstname>
                </personname>
            </author>
            <author>
                <personname>
                    <surname>Budnitz</surname>
                    <firstname>DS</firstname>
                </personname>
            </author>
            <citetitle pubwork="webpage">US Emergency Department Visits for Outpatient Adverse Drug
                Events</citetitle>
            <bibliosource>JAMA</bibliosource>
            <pubdate>2016</pubdate>
            <volumenum>316</volumenum>
            <issuenum>(20)</issuenum>
            <pagenums>2115-2125</pagenums>
        </biblioentry>

    <biblioentry>
      <author>
        <orgname>U.S. National Library of Medicine</orgname>
      </author>

      <citetitle pubwork="webpage">ARIXTRA- fondaparinux sodium injection,
      solution [Mylan Institutional LLC]</citetitle>

      <pubdate>Revised October 2015</pubdate>

      <bibliomisc>
        <link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3b30c68-cf45-4b46-8ba6-72090f7ba01a"/>
      </bibliomisc>
    </biblioentry>

    <biblioentry>
      <author>
        <orgname>U.S. National Library </orgname>
      </author>

      <citetitle pubwork="webpage">ASPIRIN 81 MG- aspirin tablet, coated
      [DOLGENCORP, LLC]</citetitle>

      <pubdate>Revised January 2017</pubdate>

      <bibliomisc>
        <link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4064039-2345-4227-b83d-54dc13a838d3"/>
      </bibliomisc>
    </biblioentry>

    <biblioentry>
      <author>
        <orgname>U.S. National Library of Medicine</orgname>
      </author>

      <citetitle pubwork="webpage">ELIQUIS- apixaban tablet, film coated
      [Cardinal Health]</citetitle>

      <pubdate>Revised March 2017</pubdate>

      <bibliomisc>
        <link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175"/>
      </bibliomisc>
    </biblioentry>

    <biblioentry>
      <author>
        <orgname>U.S. National Library of Medicine</orgname>
      </author>

      <citetitle pubwork="webpage">ENOXAPARIN SODIUM- enoxaparin sodium
      injection [Amphastar Pharmaceuticals, Inc.]</citetitle>

      <pubdate>Revised June 2017</pubdate>

      <bibliomisc>
        <link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab8118dc-aca8-478b-8290-a468cbe36ae1"/>
      </bibliomisc>
    </biblioentry>

    <biblioentry>
      <author>
        <orgname>U.S. National Library of Medicine</orgname>
      </author>

      <citetitle pubwork="webpage">FRAGMIN- dalteparin sodium injection,
      solution [Pfizer, Inc.]</citetitle>

      <pubdate>Revised March 2009</pubdate>

      <bibliomisc>
        <link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=529711c6-6029-4e50-8ece-c0e59b06ff38"/>
      </bibliomisc>
    </biblioentry>

    <biblioentry>
      <author>
        <orgname>U.S. National Library of Medicine</orgname>
      </author>

      <citetitle pubwork="webpage">HEPARIN SODIUM- heparin sodium injection
      [Pfizer Laboratories Div Pfizer Inc]</citetitle>

      <pubdate>Revised August 2016</pubdate>

      <bibliomisc>
        <link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56dc3074-f1c5-45a3-b923-f1d14858e06d"/>
      </bibliomisc>
    </biblioentry>

    <biblioentry>
      <author>
        <orgname>U.S. National Library of Medicine</orgname>
      </author>

      <citetitle pubwork="webpage">PRADAXA- dabigatran etexilate mesylate
      capsule [Boehringer Ingelheim Pharmaceuticals Inc.]</citetitle>

      <pubdate>Revised July 2017</pubdate>

      <bibliomisc>
        <link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9"/>
      </bibliomisc>
    </biblioentry>

    <biblioentry>
      <author>
        <orgname>U.S. National Library of Medicine</orgname>
      </author>

      <citetitle pubwork="webpage">WARFARIN SODIUM- warfarin tablet [Exelan
      Pharmaceuticals Inc.]</citetitle>

      <pubdate>Revised May 2016</pubdate>

      <bibliomisc>
        <link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0cc4511-e656-4b6d-96cd-e02e76173b9d"/>
      </bibliomisc>
    </biblioentry>

    <biblioentry>
      <author>
        <orgname>U.S. National Library of Medicine</orgname>
      </author>

      <citetitle pubwork="webpage">XARELTO- rivaroxaban tablet, film coated
      [Avera McKennan Hospital]</citetitle>

      <pubdate>Revised December 2015</pubdate>

      <bibliomisc>
        <link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1166231a-b23a-4c86-8cda-45d41b724e57"/>
      </bibliomisc>
    </biblioentry>
  </bibliography>

  <appendix>
    <title>Existing Sample VA Artifacts</title>
        <para>The following sample artifacts are referenced from the Portland VAMC.</para>

    <figure>
      <title>Surgical Inpatient Menu</title>

      <mediaobject>
        <alt>Screenshot of surgical inpatient menu for all of the surgical
        specialties.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig1Surgicalinpatientmenu.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>General Surgery Inpatient Orders</title>

      <mediaobject>
        <alt>Screenshot of surgery inpatient admit, preoperative, and
        postoperative orders.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig2Generalsurgeryinpatient.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>DVT Surgical Prophylaxis Orders</title>

      <mediaobject>
        <alt>Screenshot of DVT surgical prophylaxis preoperative and general
        prophylaxis.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig3DVTsurgicalprohylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Cardiothoracic Surgery DVT Preoperative Prophylaxis Options</title>

      <mediaobject>
        <alt>Prophylaxis options, early ambulation, TED use, and heparin
        dosing.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig4Prohylaxisoptions.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Early Ambulation Order - Preoperative Low DVT Risk</title>

      <mediaobject>
        <alt>Screenshot of early ambulation for preoperative low risk, up out
        of bed.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig5Earlyambulation.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Reason for Request for Mechanical DVT</title>

      <mediaobject>
        <alt>Screenshot of check boxes for a reason for request for mechanical
        DVT.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig6ReasonforrequestmechanicalDVT.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>ENT DVT Preoperative Prophylaxis - Low and Medium Risk</title>

      <mediaobject>
        <alt>Screenshot of ENT DVT prohylaxis low and medium risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig7ENTDVTprohylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Early Ambulation Orders - Preoperative Low DVT Risk</title>

      <mediaobject>
        <alt>Screenshot of preoperative low risk DVT nursing screen.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig8preoplowdvtrisk.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>General Surgery Preoperative DVT Prophylaxis Options</title>

      <mediaobject>
        <alt>Screenshot of general surgery preoperative prophylaxis, average
        risk, and patients older than 60 years.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig9Generalsurgeryprohylaxisoptions.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>OB-GYN Preoperative DVT Prophylaxis - Low, Medium, and High Risk</title>

      <mediaobject>
        <alt>Screenshot of OB-GYN preoperative prophylaxis with low, medium,
        and high risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig10obgynpreoperativeprohylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Hospital Specialty Medicine DVT Prophylaxis - Low, Medium, and High Risk</title>

      <mediaobject>
        <alt>Screenshot of hospital speciality medicine DVT prophylaxis with
        low, medium, and high risk,plus contraindications</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig11hospitalspecialitymedicineprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Exemplar Alert Contraindication for Pharmacologic DVT</title>

      <mediaobject>
        <alt>Screenshot of DVT recent hemorrhage and contraindications within
        the last 6 months.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig12dvtrecenthemorrhage.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Neurology Preoperative DVT Prophylaxis - Low, Medium, and High
      Risk</title>

      <mediaobject>
        <alt>Screenshot of neurology preoperative DVT prophylaxis with low,
        medium, and high risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig13neurologypreopprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Neurosurgery Preoperative DVT Prophylaxis - Low, Medium, High, and Very High
                Risk</title>

      <mediaobject>
        <alt>Screenshot of neurosurgery DVT prophylaxis with low, medium,
        high, and very high risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig14neurosurgerydvtprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Orthopedic DVT Preoperative Prophylaxis</title>

      <mediaobject>
        <alt>Screenshot of Orthopedic DVT preoperative prophylaxis hip fracture patient and renal
                    insufficiency.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig15orthopedicpreoperativeprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Urologic Surgery Preoperative DVT Prophylaxis - Low, Medium, and High Risk</title>

      <mediaobject>
        <alt>Screenshot of urologic surgery DVT prophylaxis with low, medium,
        and high risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig16urologicsurgeryprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Vascular Surgery Preoperative DVT Prophylaxis - Very Low, Low, Medium, and High
                Risk</title>

      <mediaobject>
        <alt>Screenshot of vascular surgery DVT prophylaxis with very low,
        low, medium, and high risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig17vascularsurgerydvtprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Vascular Surgery Preoperative DVT Prophylaxis - Very Low, Low, Medium, and High
                Risk</title>

      <mediaobject>
        <alt>Screenshot of vascular surgery DVT prophylaxis with very low,
        low, medium, and high risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig18vascularsurgerylowmediumhighrisk.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Postoperative DVT Prophylaxis</title>

      <mediaobject>
        <alt>Screenshot of postoperative DVT prophylaxis options for specialty
        surgeries.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig19postoperativedvtprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Cardiothoracic Surgery Postoperative DVT Prophylaxis</title>

      <mediaobject>
        <alt>Screenshot of cardiothoracic surgery DVT prophylaxis with
        contraindication choices.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig20cardiothoracicdvtprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>DVT Prophylaxis in Presence of a Bleeding Diathesis</title>

      <mediaobject>
        <alt>Screenshot of reason for request DVT bleed diathesis.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig21dvtbleedingdiathesis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>ENT DVT Postoperative Prophylaxis </title>

      <mediaobject>
        <alt>Screenshot for ENT DVT postoperative prophylaxis patients with
        very low, low, medium, and high risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig22entdvtprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>General Surgery DVT Postoperative Prophylaxis</title>

      <mediaobject>
        <alt>Screenshot of general surgery DVT prophylaxis patients with
        comorbidities, high risk for obesity or malignancy.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig23generalsurgerydvtprophylaxis.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>OB-GYN DVT Postoperative Prophylaxis</title>

      <mediaobject>
        <alt>Screenshot of OB-GYN postoperative DVT prophylaxis for low,
        medium, and high risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig24obgynlowmediumhighrisk.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Neurosurgery DVT Postoperative Prophylaxis</title>

      <mediaobject>
        <alt>Screenshot of neurosurgery DVT postoperative prophylaxis options,
        including recent postoperative.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig25neurosurgeryoptions.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Orthopedic Surgery DVT Postoperative Prophylaxis</title>

      <mediaobject>
        <alt>Screenshot of orthopedic surgery option for DVT prophylaxis, hip
        fracture, and arthroplasty.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig26orthopedicsurgeryoptions.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Urologic Surgery DVT Postoperative Prophylaxis</title>

      <mediaobject>
        <alt>Screenshot for urologic surgery DVT prophylaxis for low, medium,
        high, and very high risk.</alt>

        <imageobject>
          <imagedata align="center"
                     fileref="images/Fig27urologicsurgerylowmediumhighrisk.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>

    <figure>
      <title>Vascular Surgery DVT Postoperative Prophylaxis</title>

      <mediaobject>
        <alt>Screenshot for vascular surgery DVT prophylaxis options for
        patients with comorbidities.</alt>

        <imageobject>
          <imagedata align="center" fileref="images/Fig28vascularsurgeryoptions.png" scalefit="1" width="100%" contentdepth="100%"/>
        </imageobject>
      </mediaobject>
    </figure>
  </appendix>
    <appendix>
        <title>Basic Laboratory Panel Definition</title>
        <itemizedlist>
            <listitem>
                <para>Blood Urea Nitrogen</para>
            </listitem>
            <listitem>
                <para>Calcium</para>
            </listitem>
            <listitem>
                <para>Chloride</para>
            </listitem>
            <listitem>
                <para>CO2 (Carbon Dioxide, Bicarbonate)</para>
            </listitem>
            <listitem>
                <para>Creatinine</para>
            </listitem>
            <listitem>
                <para>Glucose</para>
            </listitem>
            <listitem>
                <para>Potassium</para>
            </listitem>
            <listitem>
                <para>Sodium</para>
            </listitem>
        </itemizedlist>
    </appendix>

  <appendix>
    <title>VTE Guidelines</title>

    <para>American College of Chest Physicians pregnancy anticoagulation
    guidelines (<link
    xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278054/"/>&gt;</para>
  </appendix>

    <glossary role="auto"><title>Acronyms</title></glossary>
</book>
